Sign in
Taking people in United StatesNo phase

Looks at infant outcomes after pregnant women with eczema use ruxolitinib or steroid creams

Compares infant outcomes in pregnant women with eczema using ruxolitinib or steroid creams.

Key facts

Who runs it
Incyte Corporation
Where
Morrisville, United StatesSee the site
Trial code
Registry title
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
Status
Recruiting
People taking part
5,621 people, planned
Started
27 Mar 2023
Expected to end
15 Aug 2028
Type of study
Observational, 2 groups
Treatments tested
  • Ruxolitinib Cream
  • TCS
Record updated
11 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The study looks at women with atopic dermatitis whose pregnancy followed approval of ruxolitinib cream. It compares women who used ruxolitinib cream with women who used a topical corticosteroid (TCS).

Age
Women aged 14 years or older at pregnancy outcome.
Sex
Women only.
Disease stage
A diagnosis of atopic dermatitis (AD) on or before the day of the first pharmacy claim for ruxolitinib cream or a TCS.
Earlier treatment
At least 1 pharmacy claim for ruxolitinib cream or a TCS, starting from 6 months before the estimated date of conception.

Main reasons for not taking part

  • One or more pharmacy claims for oral ruxolitinib or other JAK inhibitors in the exposure window for a given outcome.
  • Pregnancies that cannot be linked to an infant are left out of the infant outcomes.

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Women aged 14 years or older at pregnancy outcome
  • Pregnancy following FDA approval of ruxolitinib cream for AD on 21 SEP 2021
  • At least 1 pharmacy-dispensing claim for ruxolitinib cream (ruxolitinib-exposed cohort) or a TCS (TCS-exposed cohort)
  • A diagnosis of AD prior to or on the day of the first pharmacy claim for ruxolitinib cream (ruxolitinib-exposed cohort) or a TCS (TCS-exposed cohort) from 6 months before the estimated date of conception
  • Continuous enrollment in the database from 6 months before the estimated date of conception through the end of pregnancy
  • For infant outcomes only, linkage of mother and infant data will be required (ie, pregnancies that cannot be linked to an infant will be excluded for infant outcomes but not for pregnancy outcomes). Infants will be followed for as long as they are continuously enrolled in the database up to 1 year after birth (ie, variable follow-up for each infant). A 1-year fixed period of continuous enrollment after birth will not be imposed so as not to introduce survival bias

Who cannot take part

  • One or more pharmacy claims for oral ruxolitinib or other JAK inhibitors in the exposure window for a given outcome

Where in United States

  • Syneos Health (remote site)Morrisville, United StatesTaking people

About the trial

What the trial wants to find out

This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.

The 2 groups in the trial

  • Infants of women with AD exposed to ruxolitinib cream during pregnancy

    Treatment: Ruxolitinib Cream

  • Infants of women with AD exposed to a TCS prior to or during pregnancy

    Treatment: TCS

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pregnancy Outcomes Study of Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
Plain-language title
Looks at infant outcomes after pregnant women with eczema use ruxolitinib or steroid creamsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 December 2025